News Story: Full Text
Sponsored By
Orbus Therapeutics Inc Clinical Trial for Recurrent Anaplastic Astrocytomas
Please Click On The Above Banner For More Details
Braintumor Website


Oncolytics Biotech Inc. Announces Results of REOLYSIN(R) Treatment of Brain Cancer (Gliomas) in Animal Models (CCN Newswire)...~~~) reported today that Dr. Peter Forsyth and his research group with the Alberta Cancer Board and the University of Calgary are publishing the results of their work with REOLYSIN(R) for the treatment of human malignant gliomas (brain cancer) in animal models.......The research group also examined the ability of REOLYSIN(R) to infect and kill cancer cells from established glioma cell lines and brain tumor surgical specimens.......~~~Oncolytics has completed the initial part of formal toxicology studies examining the effects of injecting REOLYSIN(R) into the brains of test animals and have found no side effects of note.......Oncolytics researchers demonstrated that reovirus was selectively able to kill cancer cells with this particular activation and successfully demonstrated that the virus could kill human cancer cells in vitro derived from breast, prostate, pancreatic and brain tumors, as well as being able to treat tumours successfully in a number of animal models....- Jun 19 3:12 PM ET


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)



Website: http://biz.yahoo.com/ccn/010619/or_idc3drynreqdmccmzua.html

Posted on: 06/19/2001

"Yahoo - Oncolytics Biotech Inc. Announces Results of REOLYSIN(R) Treatment of Brain Cancer (Gliomas) in Animal Models"
Yahoo! Finance Finance Home - Yahoo! - Help
Canadian Corp News

[ Latest Headlines | Market Overview | News Alerts ]


Related Quotes
ONC.TO
9.70
+1.65
delayed 20 mins - disclaimer

Tuesday June 19, 3:12 pm Eastern Time

Press Release

Oncolytics Biotech Inc. Announces Results of REOLYSIN(R) Treatment of Brain Cancer (Gliomas) in Animal Models

CALGARY, ALBERTA--Oncolytics Biotech Inc. (TSE:ONC, or "Oncolytics") reported today that Dr. Peter Forsyth and his research group with the Alberta Cancer Board and the University of Calgary are publishing the results of their work with REOLYSIN® for the treatment of human malignant gliomas (brain cancer) in animal models. The results will be published in the June 20, 2001 issue of the Journal of the National Cancer Institute. Oncolytics holds the Patent rights to the pharmaceutical use of REOLYSIN® for the treatment of cancer.

Dr. Forsyth and his colleagues were able to demonstrate that nude mice with intracerebral (in the brain) gliomas treated with a single injection of REOLYSIN® administered intratumourally survived significantly longer than untreated animals in the control group (p<0.0001). The median survival times of two different glioma tumour types, U251N and U87lacZ, in untreated animals was 42 and 48 days respectively. None of the untreated animals survived through the experiment. When the experiments were terminated after 90 days, 67% and 82%, respectively, of the live virus treated animals were still alive. Live virus treated animals in both cases appeared healthy and gained weight, while untreated animals lost weight. Complete tumour regression was found in 20 of the 23 animals treated with live virus.

The research group also examined the ability of REOLYSIN® to infect and kill cancer cells from established glioma cell lines and brain tumor surgical specimens. Widespread cell killing was seen in 79% (19/24) of established glioma cell lines tested. Sixteen brain tumor surgical specimens were also tested, including nine gliomas. REOLYSIN® infected and killed all nine of the primary glioma cultures.

"The complete regression of the tumour mass in most of the live virus treated animals is very encouraging. The life span extension and weight gains found in these animals after REOLYSIN® treatment is nothing short of remarkable," said Dr. Brad Thompson, President and CEO of Oncolytics. "Oncolytics has completed the initial part of formal toxicology studies examining the effects of injecting REOLYSIN® into the brains of test animals and have found no side effects of note. We expect the combination of these results with those of Dr. Forsyth will lead to a clinical study examining the use of REOLYSIN® to treat malignant gliomas later this year."

Oncolytics is a Calgary-based biotechnology company whose focus is the development of the mammalian reovirus based product known as REOLYSIN® as a potential cancer therapeutic. The mammalian reovirus infects and kills cancer cells with an activated Ras pathway. Ras is an important component of a pathway controlling normal growth and differentiation of a cell, and when activated, may account for a large proportion of all mammalian tumours. Researchers believe that targeting this pathway could have broad potential in the treatment of many cancers. Oncolytics researchers demonstrated that reovirus was selectively able to kill cancer cells with this particular activation and successfully demonstrated that the virus could kill human cancer cells in vitro derived from breast, prostate, pancreatic and brain tumors, as well as being able to treat tumours successfully in a number of animal models. Oncolytics initiated its Phase I clinical trial on REOLYSIN® in June, 2000 and in May, 2001 filed an investigational new drug submission for a Phase II clinical trial on REOLYSIN® for the treatment of Stage T2A prostate cancers. In November 2000, the Company entered into a worldwide licensing agreement with Pfizer Inc. for the development and marketing of the reovirus for animal health applications. To find out more about Oncolytics Biotech Inc. (TSE: ONC - news), visit our website, at www.oncolyticsbiotech.com.

This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or expectations implied by these forward-looking statements.


Contact:
Oncolytics Biotech Inc.
Doug Ball, Chief Financial Officer
(403) 670-7380
(403) 283-0858
E-mail: dougballonc@aol.com
or
Oncolytics Biotech Inc.
Wayne Schnarr, Ph.D. MBA, Vice President,
Corporate Development
(403) 670-7374
(403) 283-0858
Website: www.oncolyticsbiotech.com
or
Opsis Financial
Mr. David Wolk
Investor Relations Advisor - Canada
(416) 368-8998
(416) 368-8669
E-mail: dwolk@opsis.ca
or
The Investor Relations Group
Gino De Jesus / Dian Griesel, Ph.D.
Investor Relations Advisor - United States
(212) 825-3210
(212) 825-3229
E-mail: theproteam@aol.com

Email this story - Most-emailed articles - Most-viewed articles


More Quotes and News:Oncolytics Biotech Inc (Toronto:ONC.TO - news)
Related News Categories: medical/pharmaceutical

Help


Copyright © 2001 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Copyright © 2001 Canadian Corp News. CCN Newswire All rights reserved. All news releases provided by CCN Newswire are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Questions or Comments?
"


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740